急性髓系白血病患者停用维奈克拉为基础的治疗后无治疗缓解
该回顾性研究纳入29例接受维奈克拉为基础治疗并缓解至少12个月的急性髓系白血病患者,55%持续治疗至疾病进展,45%选择停药。中位随访超过5年,停药组中位无治疗缓解持续45.8个月,数据截止时超过50%的患者仍维持持续缓解,两队列复发风险及无复发生存和总生存相似。
要点
- 29例缓解至少12个月的AML患者中,45%选择停用维奈克拉为基础的治疗。
- 停药组中位无治疗缓解持续45.8个月,数据截止时超过50%仍维持持续缓解。
- 诊断时NPM1和/或IDH2突变、无可测量残留病的完全缓解及停药前至少12个月联合治疗与持续无治疗缓解相关。
核心结论
- 部分选择停用维奈克拉为基础治疗的患者可获得无治疗缓解期,避免无限期治疗。
研究设计与样本
- 回顾性研究,纳入29例接受维奈克拉为基础治疗并缓解至少12个月的急性髓系白血病患者。
主要发现
- 55%的患者持续治疗至疾病进展,45%的患者选择停药(STOP)。
- 随访超过5年,停药组中位无治疗缓解持续45.8个月,数据截止时超过50%的患者仍维持持续缓解。
- 两队列的复发风险、无复发生存持续时间和总生存相似。
- 有利于持续无治疗缓解的因素包括诊断时NPM1和/或IDH2突变、无可测量残留病的完全缓解及停药前至少12个月维奈克拉为基础联合治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical benefit of adding venetoclax (VEN) to hypomethylating agents or low-dose cytarabine in older and/or unfit patients with newly diagnosed acute myeloid leukemia (AML) has been confirmed in phase 3 studies. With the increased uptake of VEN-based therapies for patients with AML, a pertinent question is whether treatment can be safely ceased among patients who have achieved sustained remission. We hypothesized that a proportion of patients opting to cease therapy may benefit from a treatment-free remission (TFR) period without indefinite treatment. We report the retrospective outcomes of 29 patients in remission for a minimum of 12 months on VEN-based therapy, with 55% continuing therapy until disease progression and 45% electively ceasing treatment (STOP). With follow-up exceeding 5 years, we observed a median TFR lasting 45.8 months among the STOP cohort, with >50% of patients still in sustained remission at the data cutoff. The risk of relapse and duration of relapse-free and overall survival were similar between the 2 cohorts. Factors favoring sustained TFR within the cohort included NPM1 and/or IDH2 mutation at diagnosis, complete remission without measurable residual disease, and at least 12 months of VEN-based combination therapy prior to treatment cessation.
引用
- Chua CC, Hammond D, Kent A, et al. Treatment-free remission after ceasing venetoclax-based therapy in patients with acute myeloid leukemia. Blood Adv. 2022. PMID: 35511730. doi:10.1182/bloodadvances.2022007083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。